جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

124 مُخرَج نتائج البحث عن «Meta-analysis»

مراجعةوصول مفتوح2026

Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies

Frontiers in Pharmacology · مجلد 17 · 1822157-1822157

Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.

empagliflozinnon-alcoholic fatty liver diseaseSGLT2 inhibitorshepatic steatosis
مراجعةوصول مفتوح2026

Meta-analysis of Randomized Trials in Emergency and Acute Orthopedic Trauma Comparing Aspirin and Low-Molecular-Weight Heparin for Thromboprophylaxis

Orthopedic Reviews · مجلد 18 · 163922-163922

Background: Venous thromboembolism remains an important complication after acute orthopedic trauma. Low molecular weight heparin has historically been the conventional pharmacologic standard for thromboprophylaxis, while aspirin has gained increasing clinical interest as a practical alternative. This systematic review and meta-analysis evaluated randomized controlled trial evidence comparing aspirin with low molecular weight heparin after acute orthopedic trauma. Methods: PubMed, Scopus, and Web of Science were systematically searched from database inception through March 21, 2026. Randomized controlled trials comparing aspirin with low molecular weight heparin in adults with acute orthopedic trauma requiring thromboprophylaxis were included. Primary outcomes were all cause mortality, bleeding complications, and infection related complications. Quantitative synthesis was performed where appropriate using pooled risk ratios with 95% confidence intervals under a random effects model. Venous thromboembolic outcomes were synthesized qualitatively because of heterogeneous endpoint definitions. Results: Four publications representing two independent randomized orthopedic trauma trial programs involving 12,540 participants were included. Meta analysis showed no statistically significant differences between aspirin and low molecular weight heparin for all cause mortality (risk ratio 1.02, 95% confidence interval 0.69 to 1.53), bleeding complications (risk ratio 0.96, 95% confidence interval 0.88 to 1.05), or infection related complications (risk ratio 1.05, 95% confidence interval 0.80 to 1.37). No statistical heterogeneity was observed across pooled outcomes. Conclusion: Aspirin did not demonstrate statistically significant differences from low molecular weight heparin in mortality or major safety outcomes within the currently available randomized orthopedic trauma evidence. However, comparative venous thromboembolic efficacy remains uncertain because thromboembolic outcomes could not be validly pooled. Further trauma specific randomized studies with standardized outcome reporting are needed.

aspirinlow molecular weight heparinthromboprophylaxisvenous thromboembolism
مراجعةوصول مفتوح2026

Clinical utility of artificial intelligence in prehospital emergency medical services : a systematic review and meta-analysis

Universa Medicina · مجلد 45 (2) · 294-309

BackgroundThe emergency medical services (EMS) sector presents substantial hurdles in providing excellent treatment while operating within limited resources. Artificial intelligence (AI) has significant potential in prehospital EMS, where rapid and accurate decision-making is essential. However, a comprehensive synthesis of AI’s effectiveness in this setting remains limited. The objective of this systematic review and meta-analysis was to evaluate AI’s predictive accuracy, compare its performance with human-based triage, and assess its feasibility in prehospital care. MethodsFollowing PRISMA guidelines, PubMed, Cochrane Library, and Web of Science were searched up to February 20, 2025. Fourteen peer-reviewed studies reporting quantitative outcomes were included. Study quality was assessed using the Newcastle-Ottawa Scale (median score = 7). Random-effects meta-analyses in R were conducted to synthesize area under the curve (AUC), AI-human AUC differences, and feasibility outcomes. ResultsAcross 14 studies involving 9,107,906 patients, AI demonstrated strong predictive performance with a pooled AUC of 0.874 (95% CI: 0.843–0.905). Individual study AUCs ranged from 0.805 to 0.997, with moderate heterogeneity (I²=52.3%). In eight studies, AI significantly outperformed human triage, showing a pooled AUC improvement of 0.074 (95% CI: 0.045–0.103; p<0.001), despite high heterogeneity due to varying human benchmarks. Feasibility analysis showed high clinical utility, with a pooled proportion of 0.929 and no heterogeneity (I²=0%). Funnel plots suggested slight asymmetry, but Egger’s tests indicated no significant publication bias. ConclusionArtificial intelligence demonstrated high predictive accuracy, slight superiority over human triage, and strong feasibility in prehospital care, supporting its integration into EMS with further validation and standardized reporting.

artificial intelligenceprehospital emergency medical servicesemergency medical triageprediction accuracy
مراجعةوصول مفتوح2026

Comparative Effectiveness of Antihypertensive Agents vs. Control in the Prevention and Management of Preeclampsia: A Network Meta-Analysis

Cureus · مجلد 18 (5) · e109602-e109602

Hypertensive disorders of pregnancy, particularly preeclampsia, are a leading cause of maternal and perinatal morbidity. While antihypertensive therapy is recommended, clinical uncertainty persists regarding the optimal agent to maximize maternal safety while minimizing adverse neonatal outcomes such as neonatal intensive care unit (NICU) admission. This review aimed to evaluate the comparative effectiveness and safety of pharmacological antihypertensive agents versus standard care or placebo in the management of hypertensive disorders of pregnancy through a network meta-analysis (NMA). A systematic review and frequentist random-effects NMA of randomized controlled trials (RCTs) was conducted. Major databases were searched for RCTs comparing antihypertensive agents (labetalol, nifedipine, methyldopa, hydralazine, prazosin) and controls. The primary neonatal outcome evaluated in this network was NICU admission. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Twenty-five RCTs were included in the qualitative and quantitative synthesis. The network geometry was anchored by labetalol and nifedipine. In the NMA, no individual antihypertensive agent demonstrated a statistically significant reduction in the risk of NICU admission compared to labetalol. However, probabilistic ranking (P-scores) identified methyldopa (P-score = 0.859) and hydralazine (0.791) as the most favourable interventions for minimizing NICU admissions. Nifedipine showed a slightly elevated, though non-significant, risk profile compared to labetalol (RR 1.09, 95% CI 0.80-1.49). The placebo and standard care ranked lowest. The overall certainty of evidence ranged from moderate to very low due to imprecision and indirectness. Active pharmacological management of hypertension in pregnancy is superior to placebo or standard care. While labetalol and nifedipine remain mainstays for acute blood pressure control, methyldopa and hydralazine probabilistically rank higher for minimizing NICU admissions. These findings support individualized antihypertensive selection based on clinical acuity and maternal-fetal hemodynamics.

preeclampsiahypertensive disorders of pregnancyantihypertensive drugslabetalol
مراجعةوصول مفتوح2026

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review

Cureus · مجلد 18 (5) · e108953-e108953

Nail lichen planus (NLP) is a chronic immune-mediated inflammatory disorder and one of the most challenging forms of lichen planus to treat. Conventional therapies, including intralesional corticosteroids, systemic immunosuppressants, and topical agents, are often associated with high failure rates and significant adverse effects. Janus kinase inhibitors (JAKIs) have emerged as mechanistically rational therapeutic agents because of the central role of the interferon (IFN)-JAK-signal transducer and activator of transcription (JAK-STAT) pathway in lichenoid inflammation; however, their efficacy and safety in NLP have not yet been systematically evaluated. A systematic review was conducted by searching PubMed, Scopus, and Web of Science from database inception through March 2026 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies included patients with clinically and/or histopathologically confirmed NLP and studies reporting original patient-level data of any design. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools appropriate to each study design. A cumulative time-to-response model was constructed, and a random-effects meta-analysis of standardized mean change (SMC) in nail severity scores was performed where data permitted. Thirteen studies were included with a total of 25 patients. Interventions included oral and topical tofacitinib, baricitinib, abrocitinib, upadacitinib, and topical ruxolitinib. Clinically meaningful improvement was reported across all studies, with most responses occurring within three to seven months of treatment initiation. The pooled SMC was 1.65 (95% confidence interval (CI): 0-3.59), with substantial heterogeneity (I²=87.6%). No serious adverse events were reported. Overall, JAKIs appear to be effective and well tolerated in the short term for refractory NLP, supporting their potential role as rescue therapy in selected cases. However, the current evidence remains limited and heterogeneous, underscoring the need for prospective randomized controlled trials with standardized outcome measures and longer follow-up durations.

nail lichen planusJAK inhibitorsrefractory lichen planustofacitinib
مراجعةوصول مفتوح2026

Comparative Effectiveness of Internal Fixation Versus Hemiarthroplasty and Total Hip Arthroplasty for Displaced Femoral Neck Fractures in Patients Aged ≥65 Years: A Network Meta-Analysis

Cureus · مجلد 18 (4) · e107725-e107725

The ideal surgical approach for treating displaced femoral neck fractures (FNFs) in elderly patients is a clinical debate. While internal fixation (IF), hemiarthroplasty (HA), and total hip arthroplasty (THA) represent the established treatment methods, their relative hierarchy regarding safety and efficacy has not been fully established. This study aimed to evaluate and rank these interventions using a network meta-analysis (NMA) framework. MEDLINE, Embase, CENTRAL, Web of Science, and Scopus were searched for randomized controlled trials (RCTs) comparing IF, HA, and THA in patients aged ≥65 years with acute displaced FNFs. The primary outcomes were reoperation rate and all-cause mortality. Secondary outcomes included functional scores (Harris Hip Score (HHS)), quality of life, and dislocations. A frequentist, multivariate, random-effects NMA with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment was performed. The required information size (RIS) and evidence conclusiveness were evaluated using trial sequential analysis (TSA). A treatment hierarchy was established using the surface under the cumulative ranking (SUCRA) curve analysis. Seventeen RCTs (3,223 patients) were included. Arthroplasty significantly reduced the risk of reoperation compared to IF (THA: RR 0.18, 95% CI 0.07-0.44; HA: RR 0.35, 95% CI 0.16-0.76). TSA confirmed that the cumulative evidence for the superiority of THA over IF in reducing reoperation has reached conclusive thresholds. THA achieved the highest functional recovery at 24 months compared to IF (MD 9.73, 95% CI 6.67-12.79), surpassing the minimal clinically important difference (MCID). SUCRA rankings identified THA as the superior intervention for both reoperation prevention (97.2%) and functional efficacy (99.5%). No significant differences were observed in all-cause mortality across the network. Arthroplasty is superior to IF for displaced FNFs in older adults. THA provides the most robust reduction in reoperation risk and superior functional restoration. Although HA remains a viable alternative, IF should be avoided as a primary treatment in this population because of its high failure rate.

internal fixationhemiarthroplastytotal hip arthroplastyelderly patients
مراجعةوصول مفتوح2026

Pulsed field ablation versus cryoballoon ablation for pulmonary vein isolation in atrial fibrillation: a systematic review and meta-analysis with subgroup analyses by AF type

BMC Cardiovascular Disorders · مجلد 26 (1)

BACKGROUND: Pulsed field ablation (PFA) is a non-thermal alternative to cryoballoon ablation (CBA) for pulmonary vein isolation in atrial fibrillation (AF). We compared their procedural efficiency, safety, and 1-year outcomes. METHODS: We searched PubMed, Scopus, Web of Science, CENTRAL, and Embase through October 2025 for randomized and comparative cohort studies of adults undergoing PFA or CBA. Outcomes were procedure duration, fluoroscopy time, left-atrial dwell time, periprocedural complications, and 1-year atrial arrhythmia recurrence, synthesized using random-effects meta-analyses with AF-type subgroup analyses. RESULTS: Twenty-three studies were included overall, of which 22 contributed to the quantitative synthesis. Overall, PFA shortened procedure duration versus CBA (mean difference [MD] − 11.50 min, 95% confidence interval [CI] − 15.39 to − 7.62), driven by persistent and mixed AF subgroups, while no significant difference was observed in paroxysmal AF. LA dwell time was reduced with PFA in paroxysmal AF, whereas fluoroscopy time did not differ significantly overall. Stroke, bleeding, and cardiac tamponade were comparable. PFA markedly decreased persistent (risk ratio [RR] 0.31, 95% CI 0.10–0.91) and transient (RR 0.19, 95% CI 0.07–0.53) phrenic nerve palsy. At 1 year, overall pooled analyses showed lower total atrial arrhythmia recurrence (RR 0.79, 95% CI 0.66–0.94) and AF recurrence (RR 0.72, 95% CI 0.62–0.83), with no difference in atrial flutter recurrence. CONCLUSIONS: PFA appears to offer shorter procedures and a more favorable phrenic-nerve safety profile than cryoballoon ablation, without evidence of excess major complications. Apparent 1-year efficacy advantages should be interpreted cautiously because the evidence base is dominated by observational studies and direct randomized PFA-versus-cryoballoon evidence remains limited.

pulsed field ablationcryoballoon ablationpulmonary vein isolationatrial fibrillation
مراجعةمفتوح (مستودع)2026

Network Meta-analysis of Melatonin Receptor Agonists in the Treatment of Primary Sleep Disorders: Efficacy and Safety Profile

Journal of Advanced Trends in Medical Research · مجلد 3 (2) · 65-74

Abstract Background: Melatonin receptor agonists represent an important class of medications for primary sleep disorders, but their comparative efficacy and safety remain incompletely understood. The study was to conduct a comprehensive network meta-analysis (NMA) comparing the efficacy and safety of melatonin receptor agonists for the treatment of primary sleep disorders. Methods: We searched multiple databases from inception to January 2025 for randomised controlled trials (RCTs) evaluating melatonin receptor agonists (ramelteon, tasimelteon, agomelatine and prolonged-release melatonin) in adults with primary sleep disorders. The primary efficacy outcomes were sleep onset latency (SOL), total sleep time (TST) and sleep efficiency. Safety outcomes included adverse events (AEs) and discontinuations. We performed a Bayesian NMA using random-effects models and assessed the certainty of evidence using the CINeMA approach. Results: Fifty-nine RCTs (12,437 participants) were included. All melatonin receptor agonists significantly reduced SOL compared to placebo, with mean differences ranging from −14.8 min (95% credible interval [CRL]: −19.2 to −10.4) for ramelteon to −8.2 min (95% CrI: −13.7 to −2.7) for prolonged-release melatonin. For TST, significant improvements compared to placebo were observed for ramelteon, tasimelteon and agomelatine, but not for prolonged-release melatonin. In head-to-head comparisons, no statistically significant differences were observed among melatonin receptor agonists for most efficacy outcomes. Regarding safety, melatonin receptor agonists demonstrated favorable profiles, with no significant increases in AEs compared to placebo for most agents. Treatment rankings based on surface under the cumulative ranking curve values positioned ramelteon as having the most favorable balance of efficacy and safety among melatonin receptor agonists. Conclusion: Melatonin receptor agonists are effective for improving SOL in primary sleep disorders, with ramelteon showing the most favourable efficacy-safety profile. While their effects are more modest than those of traditional hypnotics, their favourable safety profiles make them valuable options, particularly for vulnerable populations.

melatonin receptor agonistsprimary sleep disordersramelteontasimelteon
مراجعةوصول مفتوح2026

Efficacy and safety of azithromycin in preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

Frontiers in Pediatrics · مجلد 14 · 1780809-1780809

Introduction Ureaplasma colonization in preterm infants is linked to pulmonary inflammation and bronchopulmonary dysplasia (BPD). Evidence regarding the effectiveness of macrolides, including their prophylactic role in preventing BPD, remains limited. This review aimed to assess whether azithromycin reduces the incidence of BPD or death in preterm infants, with or without Ureaplasma colonization, compared with placebo or no intervention. Methods We followed PRISMA guidelines and searched PubMed, Cochrane Library, Embase, and Google Scholar for randomized controlled trials (RCTs) evaluating azithromycin in preterm infants with unknown or confirmed Ureaplasma infection. Primary outcomes were death and BPD, while secondary outcomes included hospital stay, adverse events, and ventilation or oxygen duration. Studies not focused on preterm infants, lacking Ureaplasma status, or not randomized were excluded. Results A meta-analysis of six randomized controlled trials, including 1,446 preterm infants with unknown or confirmed Ureaplasma status and sample sizes ranging from 80 to 796, compared azithromycin with placebo. No significant reduction was observed in BPD incidence [risk ratio (RR) = 0.92, 95% CI: 0.78–1.09, p = 0.35] or mortality (RR = 0.88, 95% CI: 0.66–1.18, p = 0.39). Heterogeneity was low for mortality ( I 2 = 0%) and moderate for BPD ( I 2 = 61%). Secondary outcomes showed no significant differences in mechanical ventilation days (mean difference=0.07, 95% CI: −0.78 to 0.33, p = 0.58), supplemental oxygen requirement (mean difference=−0.45, 95% CI: −0.98 to 0.07, p = 0.09), or hospitalization duration (mean difference=−0.02, 95% CI: −0.19 to 0.15, p = 0.85). Heterogeneity ( I 2 ) was 94% for supplemental oxygen, 71% for mechanical ventilation, and 0% for hospitalization duration. Risk-of-bias assessment identified two studies with low risk and four with unclear risk, indicating acceptable methodological quality. Conclusion This systematic review and meta-analysis evaluated azithromycin efficacy and safety in preventing BPD and reducing mortality in preterm infants. No significant reduction in BPD or mortality was observed with azithromycin compared with placebo. Secondary outcomes, including ventilation duration, supplemental oxygen use, and hospitalization length, showed no improvement. However, heterogeneity among secondary outcomes was moderate to high, and included studies were limited. Systematic Review Registration PROSPERO CRD42024572847.

azithromycinbronchopulmonary dysplasiapreterm infantsneonatal mortality
مراجعةوصول مغلق2026

Efficacy and safety of intravenous versus oral corticosteroid therapy in Graves’ ophthalmopathy: a systematic review and meta-analysis of randomized controlled trials

Orbit · مجلد 45 (3) · 479-487

Purpose Graves’ ophthalmopathy (GO) is an autoimmune orbital inflammatory disease associated with Graves’ disease. It can cause vision loss, facial disfigurement, and reduced quality of life. Systemic corticosteroids remain the first-line treatment for moderate-to-severe GO, administered either orally or intravenously. However, the optimal route of administration remains uncertain, with ongoing debate regarding their comparative efficacy and safety.The aim of this review is to compare the efficacy and safety of intravenous versus oral corticosteroids in the treatment of moderate-to-severe GO.Methods Randomized controlled trials were included. Risk of bias was assessed using the Cochrane RoB 2 tool. Outcomes focused on efficacy and safety of intravenous versus oral glucocorticoids in the treatment of GO.Results Five eligible RCTs involving 288 patients were analyzed. Intravenous steroids appeared to improve the clinical activity score (MD = −0.57; 95% CI: −0.82 to −0.33; p < 0.00001) and reduce the risk of Cushingoid facial features (RR = 0.17; 95% CI: 0.08 to 0.35; p < 0.00001). However, limited efficacy was observed in diplopia, proptosis, and in minimizing other steroid-related adverse events.Conclusion IV steroids were associated with more favourable outcomes and better tolerability than oral steroids in moderate-to-severe GO. Further comprehensive trials are needed to confirm long-term safety and optimize treatment protocols.

Graves' ophthalmopathyintravenous corticosteroidsoral corticosteroidsglucocorticoids
مراجعةوصول مفتوح2026

Interventions for metabolic bone disease of prematurity: A systematic review and meta-analysis

Metabolism Open · مجلد 29 · 100445-100445

Introduction: Metabolic bone disease of prematurity (MBDP) affects up to 30 % of very low birth weight infants; however, evidence regarding prevention and treatment strategies remains limited. We aimed to evaluate the efficacy and safety of nutritional, mechanical, and pharmacological interventions for MBDP. Methods: Following PRISMA 2020 guidelines, we searched five databases from inception to May 5, 2025, for studies evaluating interventions for MBDP in preterm infants (<37 weeks or <1500g). Primary outcomes included MBDP incidence, bone mineral density, and safety profiles. Random-effects meta-analyses, trial sequential analysis (TSA), and GRADE assessments were conducted. Results: Eighteen studies (1577 infants) from ten countries met inclusion criteria. Nutritional prophylaxis significantly reduced MBDP incidence by 54 % (risk ratio [RR] = 0.46, 95 % confidence interval [CI] 0.30-0.68, P-value<0.001), with early calcium/phosphorus supplementation achieving 74-84 % risk reduction. TSA confirmed conclusive evidence, with cumulative Z-score (-5.99) crossing the O'Brien-Fleming boundary at 270.9 % of required information size. Number needed to treat was five at 40 % baseline risk. Mechanical interventions improved bone mineral content by 28 % (P-value<0.01), quantitative ultrasound speed-of-sound (mean difference [MD] = 75.3 m/s, 95 % CI 45.2-105.4), and weight gain (MD = 5.11 g/kg/day, 95 % CI 3.95-6.27). Both interventions demonstrated favorable safety profiles, with mechanical protocols reporting no adverse events. Conclusions: Nutritional prophylaxis conclusively reduces MBDP incidence, while mechanical interventions effectively improve bone mineralization. Although no studies directly evaluated combined approaches, the complementary mechanisms of nutritional and mechanical interventions suggest that optimal prevention may involve integrating both strategies. Critical gaps persist in orthopedic management, necessitating future research on fracture protocols and surgical interventions.

metabolic bone disease of prematuritypreterm infantsvery low birth weight infantscalcium and phosphorus supplementation
مراجعةوصول مفتوح2026

Prophylactic mesh placement in midline laparotomy for patients with obesity: A systematic review and meta-analysis of evidence on safety, efficacy, and clinical guidelines

AIMS Medical Science · مجلد 13 (1) · 89-110

BackgroundA midline laparotomy causes an incisional hernia that is still prevalent and aggravated by obesity and comorbid conditions. Prophylactic mesh reinforcement (PMR) has also been suggested as a way to transform a high-tension suture line into a load-sharing repair, although concerns have been raised about patient selection, plane, and safety.MethodsOur preferred Reporting items for systemic review and meta-analysis (PRISMA)-compliant systematic review took randomized trials that compared PMR and primary suture in an elective midline laparotomy and was supplemented by modern meta-analyses, a network meta-analysis of mesh planes, and its safety data over long term. The main outcome was an incisional hernia (IH) at 12 months; secondary outcomes were surgical-site infection (SSI), seroma, chronic pain, reoperation, and quality of life. Grading of recommendations assessment, development and evaluation (GRADE) was used to assess the certainty.ResultsAcross randomized evidence, PMR reduced the IH with a pooled risk ratio near 0.38 (95% CI ~ 0.24–0.58) over 12–67 months. Long-term extensions confirmed the durability to five years. For obesity-restricted datasets, the effects trended towards being beneficial, but did not reach statistical significance (OR 0.59, 95% CI 0.34–1.01; p = 0.06), thus reflecting imprecision and heterogeneity. SSI did not increase with PMR in clean fields, whereas seroma was more frequent, especially with onlay placement without a consistent rise in chronic pain. Reoperation and explantation were uncommon and numerically lower after retromuscular placement than after onlay among reoperated patients. The network meta-analysis ranked onlay and retromuscular as the highest for IH prevention; taken with safety profiles, retromuscular emerged as a preferred option in experienced centers when the anatomy permits. The overall certainty for IH prevention was moderate; for obesity-restricted estimates, the overall certainty is low due to imprecision.ConclusionsIn patients with obesity, the current evidence suggests a possible benefit of PMR, but estimates remain imprecise and not statistically definitive, thus highlighting the need for targeted, adequately powered trials.

midline laparotomyincisional herniaobesityretromuscular mesh
مقالمفتوح (مستودع)2026

Clinical Phenotype and Complications of Systemic Lupus Erythematosus among Adults in Middle Eastern Populations: A Synthesis of Observational Cohorts (2021–2025)

Advanced Health Science and Technology Journal · مجلد 2 (1) · 2-10

Abstract Systemic lupus erythematosus (SLE) exhibits profound clinico-geographic heterogeneity, yet contemporary data from Middle Eastern populations remain fragmented. This synthesis of 12 observational cohorts (2021–2025) from Middle Eastern countries delineates a regional phenotype characterized by high disease activity and significant organ-threatening manifestations. Across these cohorts, SLE presents as a predominantly moderate-to-severe multisystem disorder. While mucocutaneous and musculoskeletal involvement are ubiquitous – exceeding 75% in several Egyptian registries – the high prevalence of lupus nephritis and hematologic cytopenias in Omani, Syrian, and Palestinian populations underscores a substantial burden of severe disease. The regional data further reveal a pronounced thromboinflammatory profile, with frequent reports of vasculitis, pericarditis, and both arterial and venous thrombosis, suggesting accelerated premature atherosclerosis. Neuropsychiatric involvement, encompassing seizures and cerebrovascular events, contributes significantly to cumulative morbidity. Although methodological heterogeneity among tertiary-care cohorts precludes a formal meta-analysis, the consistency of these patterns indicates that Middle Eastern SLE patients experience a disease course at the more severe end of the global spectrum. These findings highlight a critical “window of opportunity” for early intervention following initial musculoskeletal or mucocutaneous presentations. To improve long-term outcomes and reduce premature mortality, there is an urgent need for systematic organ screening, aggressive management of high-risk features, and the establishment of harmonized, population-based registries across the region to bridge existing gaps in longitudinal care.

systemic lupus erythematosusMiddle Eastern populationsclinical phenotypelupus nephritis